Who Paid My Doc Search
Menu
Organisation paid for research Program year 2024 Source: CMS Open Payments

Center for Sight

Neither a doctor nor a teaching hospital

Research payments

$1,919,172

385 payments

Through program year 2024, Center for Sight is reported as receiving $1,919,172 in research payments, across 385 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $148,432 161
2023 Research $343,021 18
2022 Research $346,572 37
2021 Research $244,381 53
2020 Research $268,128 48
2019 Research $568,639 68

Breakdown

Who paid Research payments · program years 2019–2024
  1. RxSight Inc $562,796 174 payments
  2. Glaukos Corporation $554,556 127 payments
  3. Merz North America, Inc. $290,858 11 payments
  4. Bausch & Lomb Americas Inc. $136,023 7 payments
  5. Allergan Inc. $120,142 26 payments
  6. Bausch Health US, LLC $102,291 11 payments
  7. Alcon Research LLC $74,865 10 payments
  8. Aerie Pharmaceuticals, Inc. $26,066 4 payments
  9. Ivantis, Inc $23,151 4 payments
  10. AbbVie, Inc. $17,587 6 payments
Studies the money was for Research payments · program years 2019–2024
  1. RxSight Light Adjustable Lens and Light Delivery Device New Enrollment Study $298,826 13 payments
  2. Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5 $235,939 32 payments
  3. Evaluation of the Sensitivity of the Merz Infraorbital Hollow Scale and Safety of Belotero Balance Injection for Volume Augmentation of the Infraorbital Hollow $222,380 9 payments
  4. A Prospective, Multicenter, Randomized, Active-Controlled Clinical Study to Evaluate the Safety and Effectiveness of the Envista One-Piece Hydrophobic Acrylic Trifocal Intraocular Lens in Subjects Undergoing Cataract Extraction $195,473 13 payments
  5. RxSight Light Adjustable Lens and Light Delivery Device New Enrollment Study $133,125 6 payments
  6. RxSight Light Adjustable Lens and Light Delivery Device New Enrollment Study $130,845 155 payments
  7. Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5% $80,918 14 payments
  8. M930121001 - Belotero Balance Infraorbital Hollow (Ioh) Pilot Study. $68,478 2 payments
  9. Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5% $63,854 15 payments
  10. Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5 $55,516 14 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record